{"title":"Comprehensive epidemiology of melanoma at all sites: insights from Japan's National Cancer Registry, 2016-2017.","authors":"Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Maiko Fujimori, Yosuke Uchitomi, Takahiro Higashi, Tomoyuki Satake, Chigusa Morizane, Naoya Yamazaki, Akira Kawai","doi":"10.1007/s10147-024-02675-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Melanoma is a highly malignant cancer responsible for 55 000 deaths worldwide annually. Despite its severity, its epidemiology in Japan remains understudied owing to its rarity among Asians. This study aimed to determine the incidence of melanoma in Japan using data from the National Cancer Registry.</p><p><strong>Methods: </strong>We analyzed data from patients diagnosed with melanoma in 2016 and 2017, classifying cases according to subtype using the World Health Organization (WHO) and other tumor classifications. Tumor incidence was calculated as the number of new cases divided by the corresponding population per year.</p><p><strong>Results: </strong>A total of 6176 patients were included in the study. The subtypes were distributed as follows: cutaneous (76.2%), mucosal (19.6%), uveal (2.7%), and neural organ/unknown primary melanoma (1.3%). The overall age-adjusted incidence of melanoma was 2.57 per 100 000 persons in the Japanese and 1.15 per 100 000 persons in the WHO population models.</p><p><strong>Conclusions: </strong>This study provided comprehensive epidemiological data on melanoma in Japan using population-based registry data, highlighting the relatively low incidence of melanoma compared with that worldwide and emphasizing the need for further research into its unique epidemiology in Asian populations.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"194-198"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-024-02675-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Melanoma is a highly malignant cancer responsible for 55 000 deaths worldwide annually. Despite its severity, its epidemiology in Japan remains understudied owing to its rarity among Asians. This study aimed to determine the incidence of melanoma in Japan using data from the National Cancer Registry.
Methods: We analyzed data from patients diagnosed with melanoma in 2016 and 2017, classifying cases according to subtype using the World Health Organization (WHO) and other tumor classifications. Tumor incidence was calculated as the number of new cases divided by the corresponding population per year.
Results: A total of 6176 patients were included in the study. The subtypes were distributed as follows: cutaneous (76.2%), mucosal (19.6%), uveal (2.7%), and neural organ/unknown primary melanoma (1.3%). The overall age-adjusted incidence of melanoma was 2.57 per 100 000 persons in the Japanese and 1.15 per 100 000 persons in the WHO population models.
Conclusions: This study provided comprehensive epidemiological data on melanoma in Japan using population-based registry data, highlighting the relatively low incidence of melanoma compared with that worldwide and emphasizing the need for further research into its unique epidemiology in Asian populations.
期刊介绍:
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.